Anti-inflammatory properties of acetylcholinesterase inhibitors administred in Alzheimer's disease

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 8, Issue 1, 2009, Pages 85-100

  Kamal, M A ^a   Greig, N H ^b   Reale, M ^c  

^a Enzymoics   (Australia)

^b Drug Design and Development Section   (United States)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Acetylcholine; Alzheimer's disease; Anti acetylcholinesterase; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN; C REACTIVE PROTEIN; CHEMOKINE; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2; CYTOKINE; DONEPEZIL; FREE RADICAL; GALANTAMINE; HUPERZINE A; METRIFONATE; NITRIC OXIDE SYNTHASE; PROSTANOID; RIVASTIGMINE; TACRINE; THIOCTIC ACID;

ALZHEIMER DISEASE; AMINOTRANSFERASE BLOOD LEVEL; ANTICHOLINERGIC SYNDROME; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRADYCARDIA; CELL ACTIVATION; CELL LOSS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LIVER TOXICITY; MICROGLIA; NAUSEA; NERVE CELL; NEUROPROTECTION; NONHUMAN; SIDE EFFECT; SLEEP DISORDER; SYNCOPE; VOMITING;

EID: 67651123211     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152309787580810     Document Type: Article

References (226)

1. Greig, N.H.; Giacobini, E.; Lahiri, D.K. Advances in Alzheimer therapy: development of innovative new strategies. Curr. Alzheimer Res., 2007, 4(4), 336-339.
2. Shua-Haim, J.; Smith, J.; Picard, F.; Sedek, G.; Athalye, S.; Pommier, F.; Lefèvre, G. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Clin. Drug Invest., 2008, 6, 361-374.
3. Sugimoto, H. Structure-activity relationships of acetylcholinesterase inhibitors: Donepezil hydrochloride for the treatment of Alzheimer's Disease. Pure Appl. Chem., 1999, 71, 2031-2037.
4. Sortino, M.A.; Frasca, G.; Chisari, M.; Platania, P.; Chiechio, S.; Vancheri, C.; Copani, A.; Canonico, P.L. Novel neuronal targets for the acetylcholinesterase inhibitor donepezil. Neuropharmacology, 2004, 47, 1198-1204.
5. Kamal, M.A.; Greig, N.H.; Alhomida, A.S.; Al-Jafari, A.A. Kinetics of human acetylcholinesterase inhibition by the novel experimental alzheimer therapeutic agent, tolserine. Biochem. Pharmacol. 2000, 60 (4), 561-570.
6. Kamal, M.A.; Greig, N.H.; Al-Jafari, A.A. A new, simple and economical approach to analyse the inhibition kinetics of acetylcholinesterase using tolserine. Em. Med. J., 2002, 20(3), 333-337.
7. Al-Jafari, A.A.; Kamal, M.A.; Alhomida, A.S.; Greig, N.H. Brain acetylcholinesterase inhibition kinetics of two experimental Alzheimer's disease drugs, phenserine and tolserine, in the rat. J. Biochem. Mol. Biol. Biophys., 2000, 4, 323-335.
8. Tweedie, D.; Brossi, A.; Chen, D.M.; Ge, Y-W.; Bailey, J.; Yu, Q-S.; Kamal, M.A.; Sambamurti, K.; Lahiri, D.K.; Greig, N.H. Neurine, an acetylcholine autolysis product, elevates secreted amyloidbeta protein precursor and amyloid-beta peptide levels, and lowers neuronal cell viability in culture: A role in Alzheimer's disease? J. Alzheimer's Dis., 2006, 10, 9-16.
9. Kamal, M.A; Yu, Q-S.; Holloway, H.W.; Tweedie, D.; Klein, P.; Greig, N.H. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J. Alzhemiers. Dis., 2006, 10, 43-51.
10. Kamal, M.A.; Al-Jafari, A.A.; Yu, Q-S; Greig, N.H. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. Biochem. Biophys. Acta, 2006, 1760, 200-206.
11. Kamal, M.A.; Klein, P.; Luo, W.; Li, Y.; Holloway, H.W.; Tweedie, D.; Greig, N.H. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental alzheimer therapeutic; dihydrobenzodioxepine cymserine. Neurochem. Res., 2008, 33, 745-753.
12. Kamal, M.A; Qu, X.; Yu, Q-S; Tweedie, D.; Holloway, H.W.; Li, Y.; Tan, Y.; Greig, N.H. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J. Neural Trans., 2008, 115, 889-898.
13. Demakis, G.J. Disability in Alzheimer's disease: causes, consequences, and economic considerations. J. Health Hum. Serv. Adm., 2007, 30, 292-305.
14. Rojo, L.E.; Fernández, J.A.; Maccioni, A.A.; Jimenez, J.M.; Maccioni, R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch. Med. Res., 2008, 39, 1-16.
15. Swerdlow, R.H. Pathogenesis of Alzheimer's disease. Clin Interv. Aging, 2007, 2, 347-59.
16. Rogers, J.; Mastroeni, D.; Leonard, B.; Joyce, J.; Grover, A. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int. Rev. Neurobiol., 2007, 82, 235-246
17. Heneka, M.T.; O'Banion, M.K. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol., 2007, 184, 69-91.
18. Eikelenboom, P.; Veerhuis, R.; Familian, A.; Hoozemans, J.J.; van Gool, W.A.; Rozemuller, A.J. Neuroinflammation in plaque and vascular beta-amyloid disorders: clinical and therapeutic implications. Neurodegener. Dis., 2008, 5, 190-193.
19. Hard, J.; Allsop, D. Amyloid deposition as the central event in the. etiology of Alzheimer's disease. Trends Pharmacol. Sci., 1991, 12, 383-388.
20. Hensley, K.; Carney, J.M.; Mattson, M.P.; Aksenova, M.; Harris, M.; Wu, J.F.; Floyd, R.A.; Butterfield, D.A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1994, 91, 3270-3274.
21. Aktas, O.; Ullrich, O.; Infante-Duarte, C.; Nitsch, R.; Zipp, F. Neuronal damage in brain inflammation. Arch. Neurol., 2007, 64, 185-189.
22. Selkoe, D.J. Alzheimer's disease. Genotypes, phenotype and treatments. Science, 1997, 275, 630-631.
23. Mann, D.M. The pathogenesis and progression of the pathological changes of Alzheimer's disease. Ann. Med., 1989, 21, 133-136
24. Barger, S.W.; Harmon, A.D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature, 1997, 388, 878-881.
25. Yankner, B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron., 1996, 16, 921-32.
26. Fernández, J.A.; Rojo, L.; Kuljis, R.O.; Maccioni, R.B.: The damage signals hypothesis of Alzheimer's disease pathogenesis. J. Alzheimers Dis., 2008, 14, 329-333.
27. Doraiswamy, P.M. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs, 2002, 16, 811-824.
28. Zhang, Y.W.; Xu, H. Molecular and cellular mechanisms for Alzheimer's disease: understanding APP metabolism. Curr. Mol. Med., 2007, 7, 687-696.
29. Bondareff, W.; Mountjoy, C.Q.; Roth, M.; Rossor, M.N.; Iversen, L.L.; Reynolds, G.P.; Hauser, D.L. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis. Assoc. Disord., 1987, 1, 256-262.
30. Walton, H.S.; Dodd, P.R. Glutamate-glutamine cycling in Alzheimer's disease. Neurochem Int., 2007, 50, 1052-1066.
31. Coyle, J.T.; Singer, H.; McKinney, M.; Price, D. Neurotransmitter specific alterations in dementing disorders: insights from animal models. J. Psychiatr. Res., 1984, 18, 501-512.
32. Onyango, I.G.; Khan, S.M. Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. Curr. Alzheimer. Res., 2006, 3, 339-349.
33. Chong, Z.Z.; Li, F.; Maiese, K. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain. Res. Brain Res. Rev., 2005, 49, 1-21.
34. Webber, K.M.; Casadesus, G.; Bowen, R.L.; Perry. G.; Smith, M.A. Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr. Metab. Immune Disord. Drug Targets, 2007, 7, 300-303.
35. Lahiri, D.K.; Chen, D.M.; Lahiri, P.; Bondy, S.; Greig, N.H. Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. Ann. N. Y Acad. Sci., 2005, 1056, 430-449.
36. Lahiri, D.K. Current Alzheimer Research': update on lipids, estrogen, neurotrophins and their roles in neurodegeneration. Curr. Alzheimer Res., 2008, 5, 1-3.
37. Sivaprakasam, K. Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation. Curr. Med. Chem., 2006, 13, 2179-2188.
38. Porcel, J.; Montalban, X. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. J. Neurol. Sci., 2006, 245, 177-181.
39. Francis, P.T.; Palmer, A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry, 1999, 66, 137-147.
40. Musia, A.; Bajda, M.; Malawska, B. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr. Med. Chem., 2007, 14, 2654-2679.
41. McGeer, P.L.; McGeer, E.G. The inflammatory response system of brain. Brain Res. Brain Res. Rev., 1995, 21, 195-218.
42. McGeer, P.L.; Rogers, J.; McGeer, E.G. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J. Alzheimers Dis., 2006, 9, 271-276.
43. Wyss-Coray, T.; Mucke, L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron, 2002, 35419-35433.
44. Schwab, C.; McGeer, P.L. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J. Alzheimers Dis., 2008, 13, 359-369.
45. Combs, C.K.; Johnson, D.E.; Karlo, J.C.; Cannady, S.B.; Landreth, G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci., 2000, 20, 558-567.
46. Breitner, J.C.; Zandi, P.P. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? N. Engl. J. Med., 2001, 345, 1567-1568.
47. Arvanitakis, Z.; Grodstein, F.; Bienias, J.L.; Schneider, J.A.; Wilson, R.S.; Kelly, J.F.; Evans, D.A.; Bennett, D.A. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology, 2008, 70, 2219-2225.
48. Vlad, S.C.; Miller, D.R.; Kowall, N.W.; Felson, D.T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology, 2008, 70, 1672-1677.
49. Aisen, P.S. The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis. Assoc. Disord., 2008, 22, 4-5.
50. Apelt, R.; Schliebs, J. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res., 2001, 894, 21-30.
51. Kitazawa, M.; Yamasaki, T.R.; LaFerla, F.M. Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann. N.Y. Acad. Sci., 2004, 1035, 85-103.
52. McGeer, E.G.; Klegeris, A.; McGeer, P.L. Inflammation, the complement system and the diseases of aging. Neurobiol. Aging, 2005, 26, 997.
53. Guo, J.T.; Yu, J.; Grass, D.; de Beer, F.C.; Kindy, M.S. Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J. Neurosci., 2002, 22, 5900-5909.
54. Walker, D.G.; Lue, L.F. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J. Neurosci. Res., 2005, 8, 412-425.
55. Parachikova, A.; Agadjanyan, M.G.; Cribbs, D.H.; Blurton-Jones, M.; Perreau, V.; Rogers, J.; Beach, T.G.; Cotman, C.W. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol. Aging, 2007, 28, 1821-1833.
56. Butovsky, O.; Talpalar, A.E.; Ben-Yaakov, K.; Schwartz, M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol. Cell Neurosci., 2005, 29, 381-393.
57. Shen, Y.; Meri, S. Complement activation and regulation in Alzheimer's disease. Prog. Neurobiol., 2003, 70, 463-472.
58. Webster, S.; Lue, L.F.; Brachova, L.; Tenner, A.J.; McGeer, P.L.; Terai, K.; Walker, D.G.; Bradt, B.; Cooper, N.R.; Rogers, J. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging, 1997, 18, 415-21.
59. van Beek, J.; Elward, K.; Gasque, P. Activation of complement in the central nervous system. Ann. N.Y. Acad. Sci., 2003, 992, 56-71.
60. McGeer, P.L.; McGeer, E.G. The possible role of complement activation in Alzheimer disease. Trends Mol. Med., 2002, 8, 519-523.
61. Pasinetti, G.M.; Tocco, G.; Sakhi, S.; Musleh, W.D.; DeSimoni, M.G.; Mascarucci, P.; Schreiber, S.; Baudry, M.; Finch, C.E. Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol. Dis., 1996, 3, 197-204.
62. Rogers, J.; Cooper, N.R.; Webster, S.; Schultz, J.; McGeer, P.L.; Styren, S.D.; Civin, W.H.; Brachova, L.; Bradt, B.; Ward, P.; Lieberburg, I. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1992, 89, 10016-10020.
63. Eikelenboom, P.; Veerhuis, R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging, 1996, 17, 673-680.
64. Snyder, S.W.; Wang, G.T.; Barrett, L; Ladror, U.S.; Casuto, D.; Lee, C.M.; Krafft, G.A.; Holzman, R.B.; Holzman, T.F. Complement C1q does not bind monomeric beta-amyloid. Exp. Neurol., 1994, 128, 136-142.
65. Yasojima, K.; Schwab, C.; McGeer, E.G.; McGeer, P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res., 1999, 830, 226-236.
66. Gasque, P.; Fontaine, M.; Morgan, B.P. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol., 1995, 154, 4726-4733.
67. Fonseca, M.I.; Zhou, J.; Botto, M.; Tenner, A.J. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci., 2004, 24, 6457-6465.
68. Charo, I.F.; Ransohoff, R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med., 2006, 354, 610-621.
69. Xia, M.Q.; Hyman, B.T. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J. Neurovirol., 1999, 5, 32-41.
70. Smits, H.A.; Rijsmus, A.; van Loon, J.H.; Wat, J.W.; Verhoef, J.; Boven, L.A;. Nottet, H.S. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol., 2002, 127, 160-168.
71. Lue, L.F.; Rydel, R.; Brigham, E.F.; Yang, L.B.; Hampel, H.; Murphy, G.M.; Brachova, L.; Yan, S.D.; Walker, D.G.; Shen, Y.; Rogers, J. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia, 2001, 35, 72-79.
72. Ishizuka, K.; Kimura, T.; Igata-yi, R.; Katsuragi, S.; Takamatsu, J.; Miyakawa, T. Immunohistochemical examination of phosphorylated tau in granulovacolar degeneration granules. Psychiatry Clin. Neurosci., 1997, 51, 135-138.
73. Xia, M.Q.; Qin, S.X.; Wu, L.J.; Mackay, C.R.; Hyman, B.T. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am. J. Pathol., 1998, 153, 31-37.
74. Tuppo, E.E.; Arias, H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol., 2005, 37, 289-305.
75. Amara, F.M.; Junaid, A.; Clough, R.R.; Liang, B.H. TGF-beta(1), regulation of alzheimer amyloid precursor protein mRNA expression in a normal human astrocyte cell line: mRNA stabilization. Mol. Brain Res., 1999, 71, 42-49.
76. Lombardi, V.R.; García, M.; Rey, L.; Cacabelos, R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. J. Neuroimmunol., 1999, 97, 163-171.
77. Nicoll, J.A.; Mrak, R.E.; Graham, D.I.; Stewart, J.; Wilcock, G.; MacGowan, S.; Esiri, M.M.; Murray, L.S.; Dewar, D.; Love, S.; Moss, T.; Griffin, W.S. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann. Neurol., 2000, 47, 365-368.
78. Dickson, D.W.; Lee, S.C.; Mattiace, L.A.; Yen, S.H.; Brosnan, C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia, 1993, 7, 75-83.
79. Rossi, F.; Bianchini, E. Synergistic induction of nitric oxide by beta-amyloid and cytokines in astrocytes. Biochem. Biophys. Res. Commun., 1996, 225, 474-478.
80. Aloisi, F.; Care, A.; Borsellino, G.; Gallo, P.; Rosa, S.; Bassani, A.; Cabibbo, A.; Testa, U.; Levi, G.; Peschle, C. Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. J. Immunol., 1992, 149, 2358-2366.
81. Thery, C.; Stanley, E.R.; Mallat, M. Interleukin 1 and tumor necrosis factor-alpha stimulate the production of colony-stimulating factor 1 by murine astrocytes. J. Neurochem., 1992, 59, 1183-1186.
82. Griffin, W.S.; Nicoll, J.A.; Grimaldi, L.M.; Sheng, J.G.; Mrak, R.E. The pervasiveness of interleukin-1 in alzheimer pathogenesis: a role for specific polymorphisms in disease risk. Exp. Gerontol., 2000, 35, 481-487.
83. Griffin, W.S.; Sheng, J.G.; Royston, M.C.; Gentleman, S.M.; McKenzie, J.E.; Graham, D.I.; Roberts, G.W.; Mrak, R.E. Glialneuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol., 1998, 8, 65-72.
84. Mrak, R.E.; Griffin, W.S. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol. Aging, 2001, 22, 903-908.
85. Selmaj, K.W.; Farooq, M.; Norton, W.T.; Raine, C.S.; Brosnan, C.F. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J. Immunol., 1990, 144, 129-135.
86. Heyser, C.J.; Masliah, E.; Samimi, A.; Campbell, I.L.; Gold, L.H. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc. Natl. Acad. Sci. USA, 1997, 940, 1500-1505.
87. Castell, J.V.; Andus, T.; Kunz, D.; Heinrich, P.C. Interleukin-6: The major regulator of acute-phase protein synthesis in man and rat. Ann. N. Y. Acad. Sci. USA, 1989, 557, 87-101.
88. Blasko, I.; Veerhuis, R.; Stampfer-Kountchev, M.; Saurwein-Teissl, M.; Eikelenboom, P.; Grubeck-Loebenstein, B. Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol. Dis., 2000, 7, 682-689.
89. Barger, S.W.; Horster, D.; Furukawa, K.; Goodman, Y.; Krieglstein, J.; Mattson, M.P. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl. Acad. Sci. USA, 1995, 92, 9328-9332.
90. Combs, C.K.; Karlo, J.C.; Kao, S.C.; Landreth, G.E. beta-Amyloid stimulation of microglia and monocytes results in TNFalphadependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci., 2001, 21, 1179-1188.
91. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O'Banion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimer's disease. Neurobiol. Aging, 2000, 21, 383-421.
92. Blasko, I.; Marx, F.; Steiner, E.; Hartmann, T.; Grubeck- Loebenstein, B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J., 1999, 13, 63-8.
93. Eikelenboom, P.; Zhan, S.S.; vanGool, W.A.; Allsop, D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci., 1994, 15, 447-450.
94. Eikelenboom, P.; van Gool,W.A. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J. Neural Transm., 2004, 111, 281-294.
95. Bach, J.H.; Chae, H.S.; Rah, J.C.; Lee, M.W.; Park, C.H.; Choi, S.H.; Choi, J.K.; Lee, S.H.; Kim, Y.S.; Kim, K.Y.; Lee, W.B.; Suh, Y.H.; Kim, S.S. C-terminal fragment of amyloid precursor protein induces astrocytosis. J. Neurochem., 2001, 78, 109-120.
96. Floden, A.M.; Combs, C.K. Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J. Neurosci. 2006, 26, 4644-4648.
97. Lindberg, C.; Selenica, M.L.B.; Westlind-Danielsson, A.; Schultzberg, M. β-amyloid protein structure determines the nature of cytokine release from rat microglia. J. Mol. Neurosci., 2005, 27, 1-12.
98. Benveniste, E.N.; Nguyen, V.T.; O'Keefe, G.M. Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem. Int., 2001, 39, 381-391.
99. Hanisch, U.K. Microglia as a source and target of cytokines. Glia, 2002, 40, 140-155.
100. Lee, Y.B.; Nagai, A.; Kim, S.U. Cytokines, chemokines, and cytokine receptors in human microglia. J. Neurosci. Res., 2002, 69, 94-103.
101. 2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett., 1991, 285, 111-114.
102. Ho, G.J.; Drego, R.; Hakimian, E.; Masliah, E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr. Drug Targets Inflamm. Allergy, 2005, 4, 247-256.
103. Feuerstein, G.Z.; Liu, T.; Barone, F.C. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc. Brain Metab. Rev., 1994, 6, 341-360.
104. Grammas, P.; Ovase, R. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol. Aging, 2001, 22, 837-842.
105. Rota, E.; Bellone, G.; Rocca, P.; Bergamasco, B.; Emanuelli, G.; Ferrero, P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol. Sci., 2006, 27, 33-39.
106. Szczepanik, A.M.; Funes, S.; Petko,W.; Ringheim, G.E. IL-4, IL- 10 and IL-13 modulate A beta(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol., 2001, 113, 49-62.
107. Szczepanik, A.M.; Rampe, D.; Ringheim, G.E. Amyloid-beta peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J. Neurochem., 2001, 77, 304-317.
108. Reale, M.; Iarlori, C.; Gambi, F.; Lucci, I.; Salvatore, M.; Gambi, D. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin- 1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp. Gerontol., 2005, 40, 165-171.
109. O'Banion, M.K. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit. Rev. Neurobiol., 1999, 13, 45-82.
110. Dubois, R.N.; Abramson, S.B.; Crofford, L.; Gupta, R.A.; Simon, L.S.; Van De Putte, L.B.A.; Lipsky, P.E. Cyclooxygenase in biology and disease. FASEB J., 1998, 12, 1063-73.
111. Bauer, M.K.; Lieb, K.; Schulze-Osthoff, K.; Berger, M.; Gebicke- Haerter, P.J.; Bauer, J.; Fiebich, B.L. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur. J. Biochem., 1997, 243, 726-731.
112. Hoozemans, J.J.M.; Rozemuller, A.J.M.; Janssen, I.; De Groot, C.J.A.; Veerhuis, R.; Eikelenboom, P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol., 2001, 101, 2-8.
113. Yermakova, A.; O'Banion, M.K. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr. Pharm. Des., 2000, 6, 1755-1776.
114. Minghetti, L.; Polazzi, E.; Nicolini, A.; Creminon, C.; Levi, G. Upregulation of cyclooxygenase-2 expression in cultured microglia by prostaglandin E2, cyclic AMP and non-steroidal anti-inflammatory drugs. Eur. J. Neurosci. 1997, 9, 934-940.
115. Montine, T.J.; Sidell, K.R.; Crews, B.C.; Markesbery, W.R.; Marnett, L.J.; Roberts, L.J.; Morrow, J.D. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology, 1999, 53, 1495-1498.
116. Sugimoto, Y; Narumiya, S. Prostaglandin E receptors. J. Biol. Chem., 2007, 282, 11613-11617.
117. Slawik, H.; Volk, B.; Fiebich, B.; Hull, M. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem. Int., 2004, 45, 653-660.
118. Shie, F.S.; Breyer, R.M.; Montine, T.J. Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am. J. Pathol., 2005, 166, 1163-1172.
119. Fiebich, B.L.; Schleicher, S.; Spleiss, O.; Czygan, M.; Hull, M. Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen- activated protein kinase and protein kinase C. J. Neurochem., 2001, 79, 950-958.
120. Bilak, M.; Wu, L.; Wang, Q.; Haughey, N.; Conant, K.; St Hillaire, C.; Andreasson, K. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann. Neurol., 2004, 56, 240-248.
121. Carrasco, E.; Werner, P.; Casper, D. Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress. Neurosci. Lett., 2008, 441, 44-49.
122. Ho, L.; Purohit, D.; Haroutunian, V.; Luterman, J.D.; Willis, F.; Naslund, J.; Buxbaum, J.D.; Mohs, R.C.; Aisen, P.S.; Pasinetti, G.M. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch. Neurol., 2001, 58, 487-492.
123. Kitamura, Y.; Shimohama, S.; Koike, H.; Kakimura, J.; Matsuoka, Y.; Nomura, Y.; Gebicke-Haerter, P.J.; Taniguchi, T. Identification of the region of mi transcription factor which is responsible for the synergy with PEBP2/CBF. Biochem. Biophys. Res. Commun., 1999, 254, 582-589.
124. Oka, A.; Takashima, S. Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport, 1997, 8, 1161-1164.
125. Yermakova, A.V.; O'Banion, M.K. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol. Aging, 2001, 22, 823-836.
126. Lukiw, W.J.; Bazan, N.G. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J. Neurosci. Res., 1997, 50, 937-945.
127. Candelario-Jalil, E.; Gonzalez-Falcon, A.; Garcia-Cabrera, M.; Alvarez, D.; Al Dalain, S.; Martinez, G.; Leon, O.S.; Springer, J.E. Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J. Neurochem., 2003, 86, 545-55.
128. Moore, A.H.; Olschowka, J.A.; Williams, J.P.; Okunieff, P.; O'Banion, M.K. Regulation of prostaglandin E2 synthesis after brain irradiation. Int. J. Radiat. Oncol. Biol. Phys., 2005, 62, 267-272.
129. Yermakova, A.V.; Rollins, J.; Callahan, L.M.; Rogers, J.; O'Banion, M.K. Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J. Neuropathol. Exp. Neurol., 1999, 58, 1135-1146.
130. Li, H.; Poulos, T.L. Structure-function studies on nitric oxide synthases. J. Inorg. Biochem., 2005, 99, 293-305.
131. Galea, E.; Feinstein, D.L.; Reis, D.J. Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures. Proc. Natl. Acad. Sci. USA, 1992, 89, 10945-49.
132. Kroncke, K.D.; Fehsel, K.; Kolb-Bachofen, V. Inducible nitric oxide synthase in human diseases. Clin. Exp. Immunol., 1998, 113, 147-156.
133. Bogdan, C. Nitric oxide and the immune response. Nat. Immunol., 2001, 2, 907-916.
134. Corradin, S.B.; Mauel, J.; Donini, S.D.; Quattrocchi, E.; Ricciardi- Castagnoli, P. Inducible nitric oxide synthase activity of cloned murine microglial cells. Glia, 1993, 7, 255-62.
135. Heneka, M.T.; Loschmann, P.A.; Gleichmann, M.; Weller, M.; Schulz, J.B.; Wullner, U.; Klockgether, T. Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. J. Neurochem., 1998, 71, 88-94.
136. Simmons, M.L.; Murphy, S. Induction of nitric oxide synthase in glial cells. J. Neurochem., 1992, 59, 897-905.
137. Nunomura, A.; Perry, G.; Aliev, G.; Hirai, K.; Takeda, A.; Balraj, E.K.; Jones, P.K.; Ghanbari, H.; Wataya, T.; Shimohama, S.; Chiba, S.; Atwood, C.S.; Petersen, R.B.; Smith, M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2001, 60, 759-767.
138. Wallace, M.N.; Geddes, J.G.; Farquhar, D.A.; Masson, M.R. Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques. Exp. Neurol., 1997, 144, 266-272.
139. Boje, K.M.; Arora, P.K. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res., 1992, 587, 250-256.
140. Goldstein, S.; Lind, J.; Merényi, G. Reaction of organic peroxyl radicals with •NO:2 and •NO in aqueous solution: Intermediacy of organic peroxynitrate and peroxynitrite species. J. Phys. Chem. A., 2004, 108, 1719-1725.
141. Moncada, S.R.; Palmer, M.J.; Higgs, E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 1991, 43, 109-142.
142. Moncada, C.; Lekieffre, D.; Arvin, B.; Meldrum, B. Effect of NO synthase inhibition on NMDA- and ischaemia-induced hippocampal lesions. Neuroreport., 1992, 3, 530-532.
143. Chao, C.C.; Hu, S.; Sheng, W.S.; Bu, D.; Bukrinsky, M.I.; Peterson, P.K. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia, 1996, 16, 276-284.
144. Dawson, V.L.; Brahmbhatt, H.P.; Mong, J.A.; Dawson, T.M. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology, 1994, 33, 1425-1430.
145. Demerle-Pallardy, C.; Lonchampt, M.O.; Chabrier, P.E.; Braquet, P. Nitric oxide synthase induction in glial cells: effect on neuronal survival. Life Sci., 1993, 52, 1883-1890.
146. Malinski, T. Nitric oxide and nitroxidative stress in Alzheimer's disease. J. Alzheimers Dis., 2007, 11, 207-218.
147. Szabó, C.; Ischiropoulos, H.; Radi, R. Peroxynitrite: biochemistry,. pathophysiology and development of therapeutics. Nat. Rev. Drug Discov., 2007, 6, 662-680.
148. Brown, G.C. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem. Soc. Trans., 2007, 35, 1119-1121.
149. Brown, G.C.; Bal-Price, A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol., 2003, 27, 325-355.
150. Vodovotz, Y.; Lucia, M.S.; Flanders, K.C.; Chesler, L.; Xie, Q.W.; Smith, T.W.; Weidner, J.; Mumford, R.; Webber, R.; Nathan, C.; Roberts, A.B.; Lippa, C.F.; Sporn, M.B. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med., 1996, 184, 1425-1433.
151. Smith, M.A.; Richey Harris, P.L.; Sayre, L.M.; Beckman, J.S.; Perry, G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci., 1997, 17, 2653-2657.
152. Praticò, D.; Trojanowski, J.Q. Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets? Neurobiol. Aging, 2000, 21, 441-445.
153. Eikelenboom, P.; Rozemuller, A.J.; Hoozemans, J.J.; Veerhuis, R.; van Gool, W.A. Neuroinflammation and Alzheimer disease: clinical and therapeutic implications. Alzheimer Dis. Assoc. Disord., 2000, 14, S854-61.
154. De Luigi, A.; Fragiacomo, C.; Lucca, U.; Quadri, P.; Tettamanti, M.; De Simoni, M.G. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech. Aging Devel., 2001, 122, 1985-1995.
155. Fillit, H.; Ding, W.H.; Buee, L.; Kalman, J.; Altstiel, L.; Lawlor, B.; Wolf-Klein, G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett., 1991, 129, 318-320.
156. De Luigi, A.; Pizzimenti, S.; Quadri, P.; Lucca, U.; Tettamanti, M.; Fragiacomo, C.; De Simoni, M.G.: Peripheral inflammatory response in Alzheimer's disease and multiinfarct dementia. Neurobiol. Dis., 2002, 11, 308-314.
157. Fuji, T.; Kawashima, K. An independent non-neuronal cholinergic system in lymphocytes. Jpn. J. Pharmacol., 2001, 85, 11-15.
158. Nomura, J.; Hosoi, T.; Okuma, Y.; Nomura, Y. A -induced TNF-α expression and acetylcholine action in mouse glial cells. Life Sci., 2003, 72, 2121-2126.
159. Sato, K.Z.; Fujii, T.; Watanabe, Y.; Yamada, S.; Ando, T.; Fujimoto, K.; Kawashima, K. Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. Neurosci. Lett., 1999, 266, 17-20.
160. Kawashima, K.; Fuji, T. Extraneuronal cholinergic system in lymphocytes. Pharmacol. Ther., 2000, 86, 29-48.
161. Fuji, T.; Watanebe,Y.; Inoue, T.; Kawashima, K. Upregulation of mRNA encoding the M5 muscarinic acetylcholine receptor in human T- and B-lymphocytes during immunological responses. Neurochem. Res., 2003, 28, 423-429.
162. Graham, A.J.; Ray, M.A.; Perry, E.K.; Jaros, E.; Perry, R.H.; Volsen, S.G.; Bose, S.; Evans, N.; Lindstrom, J.; Court, J.A. Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J. Chem. Neuroanat., 2003, 25, 97-113.
163. Borovikova, L.V.; Ivanova, S.; Zhang, M.; Yang, H.; Botchkina, G.I.; Watidns, L.R.; Wang, H.; Abumrad, N.; Eaton, J.W.; Tracey, K.J. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature, 2000, 405, 458-462.
164. Wang, H.; Yu, M.; Ochani, M.; Amella, C.A.; Tanovic, M.; Susarla, S.; Li, J.H.; Wang, H.C.; Yang, H.; Ulloa, L.; Al Abed, Y.; Czura, C.J.; Tracey, K.J. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature, 2003, 421, 384-388.
165. Nizri, E.; Hamra-Amitay, Y.; Sicsic, C.; Lavon, I.; Brenner, T.
166. Reale, M.; Iarlori, C.; Feliciani, C.; Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J. Alzheimer's Dis., 2008, 14, 147-159.
167. Pakaski, M.; Rakonczay, Z.; Kasa, P. Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro. Neurochem. Int., 2001, 38, 219-226.
168. Alvarez, A.; Alarcon, R.; Opazo, C.; Campos, E.O.; Munoz, F.J.; Calderon, F.H.; Dajas, F.; Gentry, M.K.; Doctor, B.P.; De Mello, F.G.; Inestrosa, N.C. Stable complexes involving acetylcholinesterase and amyloid-β peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J. Neurosci., 1998, 18, 3213-3223.
169. Gambi, F.; Reale, M.; Iarlori, C.; Salone, A.; Toma, L.; Paladini, C.; De Luca, G.; Feliciani, C.; Salvatore, M.; Salerno, R.M.; Theoharides, T.C.; Conti, P.; Exton, M.; Gambi, D. Alzheimer patients treated with an AChE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells. J. Clin. Psychopharmacol., 2004, 24, 314-21.
170. Lugaresi, A.; Di Iorio, A.; Iarlori, C.; Reale, M.; De Luca, G.; Sparvieri, E.; Michetti, A.; Conti, P.; Gambi, D.; Abate, G.; Paganelli, R. IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors. Exp Gerontol., 2004, 39, 653-57.
171. Reale, M.; Iarlori, C.; Gambi, F.; Feiciani, C.; Salone, A.; Toma, L.; De Luca, G.; Salvatore, M.; Conti, P.; Gambi, D. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J. Neuroimmunol., 2004, 148, 162-71.
172. Iarlori, C.; Gambi, D.; Gambi, F.; Lucci, I; Feliciani, C.; Salvatore, M.; Reale, M. Expression and production of two selected betachemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease. Exp. Gerontol., 2005, 40, 605-11.
173. Das, U.N. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med. Sci. Monit., 2007, 13, RA214-21.
174. Darvesh, S.; Hopkins, D.A. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J. Comp. Neurol., 2003, 11, 463, 25-43.
175. Darvesh, S.; Hopkins, D.A.; Geula, C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci., 2003, 4, 131-138.
176. Giacobini, E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol. Res., 2004, 50, 433-440.
177. Arendt, T.; Brückner, M.K.; Lange, M.; Bigl, V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem. Int., 1992, 21, 381-396.
178. Atack, J.R.; Perry, E.K.; Bonham, J.R.; Perry, R.H. Molecular forms of acetylcholinesterase and butyrylcholinesterase in human plasma and cerebrospinal fluid. J. Neurochem., 1987, 48, 1845-1850.
179. Inestrosa, N.C.; Alvarez, A.; Pérez, C.A.; Moreno, R.D.; Vicente, M.; Linker, C.; Casanueva, O.I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron, 1996, 16, 881-891.
180. Leonard, B.E. Pharmacotherapy in the treatment of Alzheimer's disease: an update. World Psychiatry, 2004, 3, 84-88
181. Knapp, M.J.; Knopman, D.S.; Solomon, P.R.; Pendlebury, W.W.; Davis, C.S.; Gracon, S.I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA, 1994, 27, 985-991.
182. Alhomida, S.; Al-Rajhi, A.S.; Kamal, M.A.; Al-Jafari, A.A. Kinetic analysis of the toxicological effect of tacrine (Cognex®) on human retinal acetylcholinesterase activity. Toxicology, 2000, 147, 33-39.
183. Al-Jafari, A.A.; Kamal, M.A.; Alhomida, A.S. Sensitivity of bovine retinal acetylcholinesterase (E.C. 3.1.1.7) toward tacrine: kinetic characterization. J. Biochem. Mol. Toxicol., 1998, 12, 245-251.
184. Kamal, M.A.; Alhomida, A.S.; Al-Rajhi, A.A.; Al-Jafari, A.A. Thermodynamic analysis of human retinal acetylcholinesterase inhibition using an anti-Alzheimer's drug, tacrine, through the development of a dual substrate and temperature model. Proc. Natl. Sci. Coun. Repub. China B, 2000, 24, 108-115.
185. Pratt, R.D. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. J. Neurol. Sci., 2002, 20, 57-65.
186. Shua-Haim, J.; Smith, J.; Picard, F.; Sedek, G.; Athalye, S.; Pommier, F.; Lefèvre, G. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Clin. Drug Investig., 2008, 28, 361-374.
187. Razay, G.; Wilcock, G.K. Galantamine in Alzheimer's disease. Expert. Rev. Neurother., 2008, 8, 9-17.
188. Unni, L.K.; Womack, C.; Hannant, M.E.; Becker, R.E. Pharmacokinetics and pharmacodynamics of metrifonate in humans. Methods Find. Exp. Clin. Pharmacol., 1994, 16, 285-289.
189. Mehl, A.; Rolseth, V.; Gordon, S.; Bjoraas, M.; Seeberg, E.; Fonnum, F. Brain hypoplasia caused by exposure to trichlorfon and dichlorvos during development can be ascribed to DNA alkylation damage and inhibition of DNA alkyltransferase repair. Neurotoxicology, 2000, 21, 165-173.
190. Bedford, C.T.; Robinson; J. The alkylating properties of organophosphates. Xenobiotic, 1972, 2, 307-337.
191. Barthel, W.F.; Alexander, B.H.; Giang, P.A.; Hall, S.A. Two organophosphorus compounds were studied, DDVP, and metrifonate (trichlorfon, O,Odimethyl2,2,2trichlorolhydroxyethylphosphonate). J. Amer. Chem. Soc., 1955, 77, 2424-2455.
192. Lovell, M.A.; Xie, C.; Xiong, S.; Markesbery, W.R. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J. Alzheimers Dis., 2003, 5, 229-239.
193. Zhang, L.; Xing, G.Q.; Barker, J.L.; Chang, Y.; Maric, D.; Ma, W.; Li, B.S.; Rubinow, D.R. Alpha-lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci. Lett., 2001, 312, 125-128.
194. Bielarczyk, H.; Gul, S.; Ronowska, A.; Bizon-Zygmanska, D.; Pawelczyk, T.; Szutowicz, A.R. RS-alpha-lipoic acid protects cholinergic cells against sodium nitroprusside and amyloid-beta neurotoxicity through restoration of acetyl-CoA level. J. Neurochem., 2006, 98, 1242-1251.
195. Holmquist, L.; Stuchbury, G.; Berbaum, K.; Muscat, S.; Young, S.; Hager, K.; Engel, J.; Münch, G. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol. Ther., 2007, 113, 154-164.
196. Szabo, S.I.; Zelles, T.; Lendvai, B. Intracellular Ca2+ dynamics of hippocampal interneurons following nicotinic acetylcholine receptor activation. Neurochem. Int., 2008, 52, 135-141.
197. Feuerbach, D.; Lingenhöhl, K.; Dobbins, P.; Mosbacher, J.; Corbett, N.; Nozulak, J.; Hoyer, D. Coupling of human nicotinic acetylcholine receptors α7 to calcium channels in GH3 cells. Neuropharmacology, 2005, 48, 215-227.
198. Teunissen, C.E.; Lütjohann, D.; von Bergmann, K.; Verhey, F.; Vreeling, F.; Wauters, A.; Bosmans; E.; Bosma, H.; van Boxtel, M.P.; Maes, M.; Delanghe, J.; Blom, H.J.; Verbeek, M.M.; Rieckmann, P.; De Bruijn, C.; Steinbusch, H.W.; de Vente, J. Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol. Aging, 2003, 24, 893-902.
199. Huberman, M.; Shalit, F.; Roth-Deri, I.; Gutman, B.; Brodie, C.; Kott, E.; Sredni, B.: Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J. Neuroimmunol., 1994, 52, 147-152.
200. Gu, L.; Tseng, S.; Homer, R.M.; Tam, C.; Loda, M.; Rollins, B.J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature, 2000, 404, 407-411.
201. Ragheb, S.; Lisak, R.P. Secretion of TH-2-type cytokines by acetylcholine receptor (AChR)-stimulated mononuclear cells. Ann. N.Y. Acad. Sci., 1998, 841, 347-350.
202. Chao, C.C.; Molitor, T.W; Hu, S. Neuroprotective role of IL-4 against activated microglia. J. Immunol., 1993, 151, 1473-1481.
203. Downen, M.; Amaral, T.D.; Hua, L.L.; Zhao, M.L.; Lee, S.C. Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia, 1999, 28, 114-127.
204. Okuma, Y.; Nomura, Y. Roles of muscarinic acetylcholine receptors in interleukin-2 synthesis in lymphocytes. Jpn. J. Pharmacol., 2001, 85, 16-19.
205. Kawashima, K.; Fujii, T.; Watanabe, Y.; Misawa, H. Synthesis of acetylcholine and expression of mRNA for muscarinic receptor subtypes in T-lymphocytes. Life Sci., 1998, 62, 1701-1705.
206. Kaneda, T.; Kitamura, Y.; Nomura, Y. Presence of m3 subtype muscarinic acetylcholine receptors and receptor-mediated increases in the cytoplasmic concentration of Ca2+ in Jurkat, a human leukemic helper T lymphocyte line. Mol. Pharmacol., 1993, 43, 356-364
207. Fujino, H.; Kitamura, Y.; Yada, T.; Uehara, T. Nomura, Y. Stimulatory roles of muscarinic acetylcholine receptors on T cell antigen receptor/ CD3 complex-mediated interleukin-2 production in human peripheral blood lymphocytes. Mol. Pharmacol., 1997, 51, 1007-1014.
208. Strom, B.T.; Lane, A.M.; George, K. The parallel, time-dependent, bimodal change in lymphocyte cholinergic binding activity and cholinergic influence upon lymphocyte-mediated cytotoxicity after lymphocyte activation. J. Immunol., 1981, 127, 705-710.
209. Greig, N.H.; Lahiri, D.K.; Sambamurti, K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int. Psychogeriatr., 2002, 14, 77-91.
210. Pavlov, V.A.; Tracey, K.J. The cholinergic anti-inflammatory pathway. Brain Behav. Immun., 2005, 19, 493-499.
211. Grando, S.A; Kawashima, K.; Wessler, I. Introduction: the nonneuronal cholinergic system in humans. Life Sci., 2003, 72, 2009-2012.
212. Arredondo, J.; Hall, L.L.; Ndoye, A.; Chernyavsky, A.I.; Jolkovsky, D.L.; Grando, S.A. Muscarinic acetylcholine receptors regulating cell cycle progression are expressed in human gingival keratinocytes. J. Periodontal. Res., 2003, 38, 79-89.
213. Nguyen, V.T.; Arredondo, J.; Chernyavsky, A.I.; Kitajima, Y.; Grando, S.A. Keratinocyte acetylcholine receptors regulate cell adhesion. Life Sci., 2003, 72, 2081-85.
214. Parrish, W.R.; Rosas-Ballina, M.; Gallowitsch-Puerta, M.; Ochani, M.; Ochani, K.; Hudson, L.Q.; Lin, X.; Patel, N.; Johnson, S.M.; Chavan, S.; Goldstein, R.; Czura, C.J.; Miller, E.J.; Al-Abed, Y.; Tracey, K.J.; Pavlov, V.A. Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling. Mol. Med., 2008, 14, 567-574.
215. Snyder, S.W.; Wang, G.T.; Barrett, L.; Ladror, U.S.; Casuto, D.; Lee, C.M.; Krafft, G.A.; Holzman, R.B.; Holzman, T.F. Complement C1q does not bind monomeric beta-amyloid. Exp. Neurol., 1994, 128, 136-142.
216. Vane, J.R.; Bakhle, Y.S.; Botting, R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 1998, 38, 97-120.
217. Giacobini, E. Cholinesterase inhibitors stabilize Alzheimer's disease. Ann. N.Y. Acad. Sci., 2000, 920, 321-327.
218. Greig, N.H.; Lahiri, D.K.; Giacobini, E. Editorial: advances in Alzheimer therapy: something old, something new, something borrowed, something blue. Curr. Alzheimer Res., 2005, 2, 275-279.
219. Ezoulin, M.J.; Liu, Z.; Dutertre-Catella, H.; Wu, G.; Dong, C.Z.; Heymans, F.; Ombetta, J.E.; Rat, P.; Massicot, F. A new acetylcholinesterase inhibitor with anti-PAF activity modulates oxidative stress and pro-inflammatory mediators release in stimulated RAW 264.7 macrophage cells. Comparison with tacrine. Int. Immunopharmacol., 2007, 7, 1685-1694.
220. Svensson, A.L.; Nordberg, A. Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells. Neuroreport., 1998, 9, 1519-1522.
221. Xiao, X.Q.; Wang, R.; Tang, X.C. Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury. J. Neurosci. Res., 2000, 61, 564-69.
222. Campanucci, V.A.; Krishnaswamy, A.; Cooper, E. Mitochondrial reactive oxygen species inactivate neuronal nicotinic acetylcholine receptors and induce long-term depression of fast nicotinic synaptic transmission. J. Neurosci., 2008, 28, 1733-1744.
223. Roy, A.; Jana, A.; Yatish, K.; Freidt, M.B.; Fung, Y.K.; Martinson, J.A.; Pahan, K. Reactive oxygen species up-regulate CD11b in microglia via nitric oxide: Implications for neurodegenerative diseases. Free Radic. Biol. Med., 2008, 45, 686-699.
224. Czura, J.C.; Friedman, S. G.; Tracey, K. J. Neural inhibition of inflammation: the cholinergic anti-inflammatory pathway. J. Endotoxin Res., 2003, 9, 409-413.
225. Pavlov, V. A.; Wang, H.; Czura, C. J.; Friedman, S. G.; Tracey,. K. J. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol. Med., 2003, 9, 125-134.
226. Kawashima, K.; Yoshikawa, K.; Fujii, Y.; Moriwaki,Y. Expression and function of genes encoding cholinergic components in murine immune cells. Life Sci., 2007, 80, 2314-2319.